Upgrade to SI Premium - Free Trial

Cellectis (CLLS)

3.04 -0.07 (2.25%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/9/26 *Est.)
- M&A (Rumor)

Latest Headlines

Cellectis (CLLS) Tops Q2 EPS by 4c August 6, 2026 5:53 PM - StreetInsider Prolynx names CFO and CSO to advance obesity drug portfolio July 15, 2026 8:01 AM - StreetInsider Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio July 15, 2026 8:00 AM - Globe NewsWire Cellectis receives FDA RMAT designation for blood cancer therapy June 9, 2026 4:31 PM - StreetInsider Barclays initiates oncology-focused biotechs with positive outlook May 28, 2026 11:05 AM - StreetInsider Barclays Starts Cellectis (CLLS) at Overweight May 28, 2026 3:36 AM - StreetInsider Full Article List